Our Stock of the Week is Alto Neuroscience, Inc. (ANRO). Alto Neuroscience is a clinical-stage biopharmaceutical company that uses an AI-enabled biomarker platform (incorporating EEG brain activity, neurocognitive assessments, and wearable data) to develop precision medicines for neuropsychiatric disorders including depression, treatment-resistant depression, and schizophrenia.
In late 2024, ANRO crashed after its schizophrenia candidate failed to meet its primary endpoint. Shares broke down again ahead of the tariff-tantrum last year, but clawed back those losses before jumping sharply higher on October 3, 2025, when the FDA granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia, an indication with no currently approved treatments. On October 20th, shares jumped again when the company announced a successful outcome from an FDA meeting for ALTO-207, a fixed-dose combination therapy for treatment-resistant depression, and closed a $50 million PIPE led by Perceptive Advisors to accelerate its development toward a potentially pivotal Phase 2b trial.
Technically, shares spent the next couple of months digesting those October gains with support along the 20-day moving average before pushing toward post-IPO highs from 2024. The stock spent the next couple of months basing at highs before inching to record high territory in mid-March. Since then, ANRO has been forming a pennant with support along the 50-day moving average, showing notable relative strength in an otherwise challenging market. As always, we will not chase any early strength on Monday morning, but would look to build a position as the chart develops.
This post is for educational purposes only! This is not advice or a recommendation. We do not give investment advice. Do not act on this post. Do not buy, sell, or trade the stocks mentioned herein. We WILL actively trade this stock differently than discussed herein. We will sell into strength and buy or sell at any time for any reason. We will actively trade into any unusual activity. At the time of this post, principals, employees, and affiliates of Shark Investing, Inc. and/or principals, clients, employees, and affiliates of Hammerhead Financial Strategies, LLC, directly or indirectly, controlled investment and/or trading accounts containing positions in ANRO at the time this was published. To accommodate the objectives of these investing and/or trading accounts, the trading in these shares will be contrary to and/or inconsistent with the information contained in this posting.
